AVMXY - Avita Medical Limited

Other OTC - Other OTC Delayed Price. Currency in USD
2.0700
-0.0875 (-4.06%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close2.1575
Open2.1500
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.0000 - 2.1500
52 Week Range0.7700 - 2.2500
Volume257,129
Avg. Volume118,385
Market Cap186.574M
Beta (3Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Business Wire22 days ago

    AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that 26 abstracts highlighting the clinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been selected for presentation at four burn conferences in early 2019. Nine of the presentations will be made at the largest burn conference, the American Burn Association (ABA) 51st Annual Meeting to be held in Las Vegas April 2-5, 2019, including a Top-Five Abstract presentation in plenary session.

  • Business Wirelast month

    AVITA Medical Announces U.S. National Market Launch of RECELL® System

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national market launch of the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of acute thermal burns in patients 18 years and older. The U.S. sales team of Regenerative Tissue Specialists and Clinical Training Specialists that joined AVITA Medical in November 2018 has been trained and fully deployed across the U.S. in support of the nationwide launch of the RECELL System.

  • Business Wire2 months ago

    AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA Medical’s RECELL® Autologous Cell Harvesting System (RECELL System) was selected as part of PM360’s 7th Annual Innovations Issue, which is published in December each year. The RECELL System was approved by the U.S. Food and Drug Administration (FDA) in September 2018 for the treatment of acute thermal burns in patients 18 years and older.

  • Business Wire2 months ago

    AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit

    AVITA Medical , a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018.

  • Business Wire3 months ago

    AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced an institutional placement of A$40.0 million (Institutional Placement) to fund the marketing and sales effort to support U.S. market launch of the RECELL® System, clinical and research and development to facilitate pipeline advancement, and general working capital requirements. Avita has received under the Institutional Placement commitments from U.S., Australian and international institutional and sophisticated investors for a placement of A$40.0 million at an issue price of A$0.080 per share, with the placement to occur in two tranches. Tranche 1 of the institutional placement, totaling A$24.5 million, is expected to settle on 7 December 2018 without the need for prior shareholder approval.

  • Business Wire3 months ago

    AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to support the U.S. market launch of the RECELL® System for the treatment of acute thermal burns. The full direct sales team of 20 healthcare professionals has joined AVITA and are in the process of completing a rigorous training program, including on-site training within burn centers, in preparation for the market launch of the RECELL System.

  • Business Wire3 months ago

    Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that key opinion leaders from five U.S. burn centers presented clinical results of the RECELL® Autologous Cell Harvesting Device (RECELL® System) at two U.S. burn conferences, the 31st Annual Southern Region Burn CME Conference held in Mobile, AL and the Northeast Region Burn Conference held in Cambridge, MA. In addition, the burn surgeons led two medical education symposiums on the use of the RECELL System at the conferences.

  • Business Wire4 months ago

    AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries

    AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a global regenerative medicine company, today announced that the commencement of a randomized, controlled clinical study of the RECELL® Autologous Cell Harvesting Device (RECELL® System) in the treatment of significant superficial partial- and mid-thickness pediatric burns, including scald injuries. The clinical trial is being conducted by the Queensland University of Technology (QUT) in collaboration with the Pegg Leditschke Children’s Burns Centre at Lady Cilento Children’s Hospital in Brisbane, QLD.

  • Business Wire4 months ago

    AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL® Autologous Cell Harvesting Device (RECELL® System) and has commenced commercial shipment of the product. The U.S. Food and Drug Administration (FDA) approved on 20 September 2018 the RECELL System to treat acute thermal burns in patients 18 years and older.

  • Business Wire4 months ago

    AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System) was held at the U.S. Midwest Region Burn Conference in Minneapolis. The symposium was led by Jeffrey Carter, MD, FACS, Medical Director of University Medical Center New Orleans Burn Center and Associate Professor of Surgery at LSU Health New Orleans School of Medicine.

  • Business Wire5 months ago

    AVITA Medical Announces Presentation of RECELL® System Effectiveness and Safety at Eastern Great Lakes Burn Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that the results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) were presented at the 46th Annual Eastern Great Lakes Burn Conference in Ann Arbor, Michigan. The results were presented by Jeffrey Carter, MD, FACS, Medical Director of University Medical Center New Orleans Burn Center & Associate Professor of Surgery at LSU Health New Orleans School of Medicine. “The RECELL System technology provides a major advancement for burn care,” said Dr. Carter.

  • Business Wire5 months ago

    AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017. The R&D Tax Credit incentive program provides a cash rebate to support companies in Australia in undertaking research and development projects. Qualifying projects undertaken by AVITA Medical qualifying for the rebate included the development of its RECELL® Autologous Cell Harvesting Device (RECELL® System), which was approved by the U.S. Food and Drug Administration (FDA) last week to treat severe thermal burns in the U.S.

  • Business Wire5 months ago

    AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.

    AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a global regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) approved the Company’s Premarket Approval (PMA) application to market the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat severe thermal burns in patients 18 years and older. The RECELL System uses a small amount of a patient’s own skin to prepare Spray-On Skin™ Cells at the point of care in as little as 30 minutes, providing a new way to treat thermal burns. The two randomized, controlled clinical trials supporting the FDA approval demonstrated that treatment of acute burn wounds with the RECELL System required substantially less donor skin than required with conventional split-thickness autografts to achieve closure of burn wounds.

  • Business Wire6 months ago

    AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch

    AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California. Effective July 1, 2018, AVITA Medical acquired the facility from a Fortune 500 manufacturer that had previously assembled the RECELL Device on a contract basis. The manufacturing runs were performed after AVITA Medical’s takeover of the facility and represent the first production activities undertaken by the Company’s own manufacturing and quality control personnel.

  • Business Wire6 months ago

    AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting Device were presented in the plenary session at the U.S. Defense Department Military Health System Research Symposium (MHSRS) in Kissimmee, Florida. The results were presented by James H. Holmes, IV, MD, FACS Wake Forest Baptist Medical Center, Winston-Salem North Carolina.

  • Business Wire6 months ago

    AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns

    FDA approves expansion of program to include up to 108 patients and 26 U.S. burn centers

  • Business Wire7 months ago

    AVITA Medical Announces Results of Extraordinary General Meeting

    AVITA Medical , a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications, announced that both resolutions presented to shareholders were approved at an Extraordinary General Meeting held today.

  • Business Wire7 months ago

    AVITA Medical Announces Expansion of Management Team to Support Planned U.S. Launch of RECELL® Device

    AVITA Medical today announced that it expanded its management team in the commercial, legal and medical affairs functions to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns.

  • Business Wire8 months ago

    AVITA Medical Announces Acquisition of Manufacturing Facility to Support Planned U.S. Launch of RECELL® Device

    AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that it has entered into an agreement to acquire a manufacturing facility to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns. The facility is currently operated by a Fortune 500 contract manufacturer that assembles the RECELL Device for AVITA Medical. AVITA Medical will take over operations of the 2,200 square meter (23,000 square foot) manufacturing plant, located in Ventura, California, effective July 1, 2018 and will retain key employees.

  • Business Wire8 months ago

    AVITA Medical Announces Presentation of RECELL® Device Clinical Trial Results at Changhai Academic Week for Burns Treatment Conference in China

    AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that results from two U.S. pivotal clinical trials and the U.S. Compassionate Use program demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting Device were presented at the 2nd Changhai Academic Week for Burns Treatment in Shanghai, China. The results were presented by Jeffrey Carter, MD, FACS, Medical Director & Associate Professor of Surgery at University Medical Center Burn Center & Louisiana State University School of Medicine, New Orleans, LA. "As Burn Surgeons we cannot choose our patients’ severity of injury, age, nor any combination of other injuries or illness that complicate their course of care," said Dr. Carter.

  • Business Wire8 months ago

    AVITA Medical RECELL® Device Pivotal Trial Results in Second-Degree Burns Published in Journal of Burn Care & Research

    AVITA Medical announced today that results from a pivotal clinical trial demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting Device in the treatment of deep partial-thickness burns were published for the first time in a major peer-reviewed journal, the Journal of Burn Care & Research.

  • Business Wire9 months ago

    AVITA Medical Announces Institutional Placement of A$16.0 Million to Support U.S. Commercialization of the RECELL® Device

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications, today announced an institutional placement of A$16.0 million to prepare for the planned U.S. launch of the RECELL® Device in the treatment of severe burns. Avita has received commitments from international and Australian institutional and sophisticated investors for a placement of A$16.0 million at an issue price of A$0.050 per share, with the placement to occur in two tranches.

  • Business Wire9 months ago

    AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model

    AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from a study validating the predicted outcomes and costs from an acute burns health economic model were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland. The landmark model is the first validated economic model available to assess the costs and clinical impact of new interventions versus standard of care for inpatient treatment of acute burns along the burn care continuum. The model demonstrates the ability to predict the cost-effectiveness, incremental costs and the budget impact of different care management approaches.